Evidence map›Paper›PMID 29431029›Full record

ArticleTissue engineering. Part A2018

Oversized Biodegradable Arterial Grafts Promote Enhanced Neointimal Tissue Formation.

Cameron Best, Takuma Fukunishi, Joseph Drews, Ramak Khosravi, Kan Hor, Nathan Mahler, Tai Yi, Jay D Humphrey, Jed Johnson, Christopher K Breuer and 1 more

Abstract read
In one paragraph

Article in Tissue engineering. Part A, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Systematic Review of Tissue-Engineered Vascular Grafts.Frontiers in bioengineering and biotechnology · 2021
    Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Cameron Best1 Tissue Engineering and Surgical Research, The Research Institute , Nationwide Children's Hospital, Columbus, Ohio.
Takuma Fukunishi3 Department of Surgery, Division of Cardiac Surgery, Johns Hopkins Hospital , Baltimore, Maryland.
Joseph Drews1 Tissue Engineering and Surgical Research, The Research Institute , Nationwide Children's Hospital, Columbus, Ohio.
Ramak Khosravi5 Department of Biomedical Engineering, Yale University , New Haven, Connecticut.
Kan Hor6 Department of Cardiology, Nationwide Children's Hospital , Columbus, Ohio.
Nathan Mahler1 Tissue Engineering and Surgical Research, The Research Institute , Nationwide Children's Hospital, Columbus, Ohio.
Tai Yi1 Tissue Engineering and Surgical Research, The Research Institute , Nationwide Children's Hospital, Columbus, Ohio.
Jay D Humphrey5 Department of Biomedical Engineering, Yale University , New Haven, Connecticut.
Jed Johnson7 Nanofiber Solutions , Hilliard, Ohio.
Christopher K Breuer1 Tissue Engineering and Surgical Research, The Research Institute , Nationwide Children's Hospital, Columbus, Ohio.
Narutoshi Hibino3 Department of Surgery, Division of Cardiac Surgery, Johns Hopkins Hospital , Baltimore, Maryland.

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007205 · NIGMS · YALE UNIVERSITY · PI KAZMIERCZAK, BARBARA I · 1985 to 2019
$42.9M
Improving Tissue Engineered Vascular Graft Performance via Computational ModelingR01HL139796 · NHLBI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI BREUER, CHRISTOPHER KANE, HUMPHREY, JAY D. · 2018 to 2025
$6.4M
Mechanisms of Vascular Neotissue Formation In Tissue Engineered Vascular GraftsR01HL098228 · NHLBI · YALE UNIVERSITY · PI BREUER, CHRISTOPHER KANE · 2010 to 2018
$3.6M
Development of an Improved Vascular Graft for Use in Congenital Heart SurgeryR01HL128847 · NHLBI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI BREUER, CHRISTOPHER KANE · 2016 to 2019
$2.8M
Computational Model Driven Design of Tissue Engineered Vascular GraftsR01HL128602 · NHLBI · YALE UNIVERSITY · PI BREUER, CHRISTOPHER KANE, HUMPHREY, JAY D. · 2015 to 2018
$2.2M
NHLBI NIH HHS R01 HL098228NHLBI NIH HHS R01 HL128602NHLBI NIH HHS R01 HL128847NHLBI NIH HHS R01 HL139796NIGMS NIH HHS T32 GM007205
6 · The paper itself

Abstract

Most tissue-engineered arterial grafts are complicated by aneurysmal dilation secondary to insufficient neotissue formation after scaffold degradation. The optimal graft would form an organized multilayered structure with a robust extracellular matrix that could withstand arterial pressure. The purpose of the current study was to determine how oversizing a biodegradable arterial scaffold affects long-term neotissue formation. Size-matched (1.0 mm, n = 11) and oversized (1.6 mm, n = 9) electrospun polycaprolactone/chitosan scaffolds were implanted as abdominal aortic interposition grafts in Lewis rats. The mean lumen diameter of the 1.6 mm grafts was initially greater compared with the native vessel, but matched the native aorta by 6 months. In contrast, the 1.0 mm grafts experienced stenosis at 6 and 9 months. Total neotissue area and calponin-positive neotissue area were significantly greater in the 1.6 mm grafts by 6 months and similar to the native aorta. Late-term biomechanical testing was dominated by remaining polymer, but graft oversizing did not adversely affect the biomechanics of the adjacent vessel. Oversizing tissue-engineered arterial grafts may represent a strategy to increase the formation of organized neotissue without thrombosis or adverse remodeling of the adjacent native vessel by harnessing a previously undescribed process of adaptive vascular remodeling.

Indexed as

Absorbable ImplantsBlood Vessel ProsthesisAneurysmAnimalsChitosanFemalePolyestersRatsRats, Inbred LewTissue ScaffoldsTunica IntimaChitosanpolycaprolactonePolyesterschitosanelectrospinningpolycaprolactonerat modelsize mismatchtissue-engineered arterial graft

Identifiers

PMID29431029
PMCPMC6079650

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.